- Headquarters
- Seattle, Washington
- Employees
- 11–50
- Founded
- 1985
- Business Model
- B2B
About
Cascadian Therapeutics was a Seattle-based biopharmaceutical company focused on developing targeted therapies for cancer. The company developed tucatinib (ONT-380), a highly selective HER2 inhibitor for HER2-positive breast cancer. Cascadian was acquired by Seattle Genetics in February 2018 for $614 million; tucatinib subsequently received FDA approval as Tukysa in 2020.